DGAP-News: myoscience Named Winner of the 2014 Red Herring Top 100 North America Award

        Print
| Source: EQS Group AG
DGAP-News: myoscience /
myoscience Named Winner of the 2014 Red Herring Top 100 North America
Award

22.05.2014 / 00:39

---------------------------------------------------------------------

REDWOOD CITY, Calif., 2014-05-22 00:38 CEST (GLOBE NEWSWIRE) --
California based myoscience, inc., makers of the revolutionary iovera* system
for treatment of peripheral nerves, has been named a winner of the prestigious
Red Herring 2014 Top 100 North America Award. As a winner, myoscience joins a
short list that honors the year's most promising private companies. Starting
from a field of over 3,000 candidates, myoscience was selected as a Top 100
winner by Red Herring. 

Award winners were selected using a rigorous evaluation process that included
both quantitative and qualitative criteria, such as financial performance,
technological innovation and intellectual property, management quality,
business model, customer footprint and market penetration. 

Myoscience's groundbreaking iovera* treatment utilizes the body's natural
response to cold to deliver immediate results for both therapeutic and
aesthetic applications. The iovera* system is FDA cleared for the treatment of
pain in the United States and is approved in the European Union and Canada for
the treatment of wrinkles. 

'In 2014, selecting the top 100 achievers was by no means a small feat,' said
Alex Vieux, publisher and CEO of Red Herring. 'In fact, we had the toughest
time in years because so many entrepreneurs had crossed significant milestones
so early. But after much thought, rigorous contemplation and discussion, we
narrowed our list down from all the candidates across North America to the top
100 winners. We believe myoscience embodies the vision, drive and innovation
that define a successful entrepreneurial venture. Myoscience should be proud of
its accomplishment, as the competition was very strong.' 

'We are proud of our team, grateful to our investors, and very honored to have
been selected for this highly coveted distinction,' said myoscience CEO Clint
Carnell. 'This selection further validates the hard-work and dedication of our
team in bringing this remarkable platform technology to patients around the
world.' 

ABOUT MYOSCIENCE

Silicon Valley, California-based myoscience is a privately-held medical device
company committed to making its platform technology, Focused Cold Therapy, the
standard of care for the treatment of peripheral nerve conditions. Focused Cold
Therapy is the patented technology delivered by the iovera:o system. The
iovera:o 
system is currently approved in Europe and Canada for temporary wrinkle
reduction, temporary pain reduction and treatment of dermatologic conditions,
and is indicated in the United States for use in pain management and general
surgical use. For more information, please visit www.myoscience.com. 

(c) 2014 myoscience. All rights reserved. iovera* and Focused Cold Therapy are
trademarks of myoscience.   MKT-0250 REV A 


         CONTACT: 1600 Seaport Blvd., Ste. 450  /  Redwood City, CA
         Tel: 650.474.2600 /  iovera.com
         
         MEDIA RELATIONS
         Jay Patel / jay.patel@hypertonic.com
News Source: NASDAQ OMX


End of Corporate News

---------------------------------------------------------------------

22.05.2014 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------


Language:    English        
Company:     myoscience     
 
 
             United States  
ISIN:        US9902131674   
 
 
End of News    DGAP News-Service  
---------------------------------------------------------------------  
269921 22.05.2014